Figure 4 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

<jats:p>&lt;p&gt;Oncogenic driver alterations. &lt;b&gt;A,&lt;/b&gt; ctDNA oncogenic driver alteration landscape at baseline showing only cases harboring an alteration. Kaplan–Meier plots for OS by (&lt;b&gt;B&lt;/b&gt;) &lt;i&gt;KRAS&lt;/i&gt; mutation status and treatment arm, (&lt;b&gt;C&lt;/b&gt;) &lt;i&gt;EGFR&lt;/i&gt;, &lt;i&gt;ALK&lt;/i&gt;, &lt;i&gt;ROS1&lt;/i&gt;, and &lt;i&gt;RET&lt;/i&gt; combined mutation status based on ctDNA only (ctDNA BEP), and (&lt;b&gt;D&lt;/b&gt;) &lt;i&gt;EGFR&lt;/i&gt;, &lt;i&gt;ALK&lt;/i&gt;, &lt;i&gt;ROS1&lt;/i&gt;, &lt;i&gt;RET&lt;/i&gt;, &lt;i&gt;NTRK&lt;/i&gt;, and &lt;i&gt;MET&lt;/i&gt; combined mutation status based on ctDNA and eCRFs (ITT population). &lt;i&gt;KRAS&lt;/i&gt; mutation status was defined as either WT or mutated, independent of other genes’ alteration status. &lt;i&gt;EGFR&lt;/i&gt;, &lt;i&gt;ALK&lt;/i&gt;, &lt;i&gt;ROS1&lt;/i&gt;, and &lt;i&gt;RET&lt;/i&gt; mutation status and &lt;i&gt;EGFR&lt;/i&gt;, &lt;i&gt;ALK&lt;/i&gt;, &lt;i&gt;ROS1&lt;/i&gt;, &lt;i&gt;RET&lt;/i&gt;, &lt;i&gt;NTRK&lt;/i&gt;, and &lt;i&gt;MET&lt;/i&gt; mutation status were defined as mutant if an alteration occurred in at least 1 of the genes, independent of other alterations. CN, copy number; MUT, mutant.&lt;/p&gt;</jats:p>